No Data
HAITONG SEC: The respiratory multiplex testing market is expected to continue expanding. It is recommended to pay attention to InnoTek (688253.SH) and others.
HAITONG SEC estimates that under neutral expectations, there will be a market space of 8.1 billion yuan for in-house respiratory testing products.
Innote: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
InnoTek (688253.SH): has repurchased 1.1633% of the company's shares.
Gelonghui, on January 24, reported that InnoTek (688253.SH) announced that as of January 24, 2025, the company bought back 1,587,406 shares through the trading system of the Shanghai Stock Exchange via a centralized bidding approach, accounting for 1.1633% of the total share capital of 136,458,196 shares. The highest price for the buyback was 45.37 yuan per share, and the lowest price was 28.62 yuan per share, with a total payment of 62,012,554.60 yuan (excluding stamp duty, transaction commission, and other trading costs).
Innote: Voluntary Disclosure Notice for 2024 Annual Results Forecast
Voluntary Disclosure Notice for 2024 Annual Results Forecast
Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
